Description
Votrient 400mg Tablet 30’S votrient 400mg tablets, a vital component in cancer care, are designed to help manage advanced renal cell carcinoma. Each tablet contains Pazopanib, an angiogenesis inhibitor that targets tumor growth. With 30 tablets per pack, this medication is administered orally once daily. Votrient is FDA-approved and has demonstrated efficacy in slowing the progression of renal cell carcinoma, improving patient outcomes. Consult with your healthcare provider for dosage and usage instructions to ensure optimal results.
Reviews
There are no reviews yet.